Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
BALL, SG; COWAN, JC; WINTER, C; MACKINTOSH, AF, TAN, LB; CALDICOTT, L; CHANNER, K; HAWLEY SK, WILSON A, DEWS I, KADR H, STANTON J, STATUCH C, STEPHENS JD, BERKIN KE, DAVIES S, RAJ MVJ, CALLAGHAN TS, JOSEPH S, RAO AC, HAMBLETON D, HORNUNG RS, RODRIGUES E, ROBERTS H, WALLER D, WARNER N, PUGH SE, RAMAKRISHNAN N, SEKAR M, BLACKWOOD RA, ROBINSON P, CLARK M, ROBSON RH, PICKENS PT, TILDESLEY G, WHITE RWB, KELLY P, WILSON JI, JONES S, KINGDOM C, PATTERSON DLH, BENTLEY A, GUPTA S, HENDRY WG, DAVIDSON C, GLENNON P, BISHOP A, KLUTH D, MOONEY A, WILKINSON P, ANTHONY TP, GHOSH AK, ROBSON D, MCALEER B, VARMA MPS, LARKIN H, KADDOURA S, KNIGHT C, SUTTON G, CLARK RS, BEEN M, RAMAN A, BROWN AK, FOALE R, SHAHI J, BORLAND C, JAYASURIYA TG, SOMASUNDRAM U, EKDAHL S, HANSEN S, BROQVIST M, DAHLSTROM U, KONGSTAD O, CLINE C, ERHARDT L, WILLENHEIMER R, BERGLUND H, NYQUIST O, NYMAN P, URSING D, JENSEN S, GYLAND F, LINNE R, RAGNARTZ T, WATZ R, FREITAG M, OLSSON L, HALLGREN J, LINDVALL P, BERGIN C, CREAN P, ELGUYLANI N, MCADAMS B, MORAIS D, SHEAHAN R, MCKENNA J, MURRAY D, SULLIVAN P, FENNELL W, KEARNEY P, VAUGHAN C, GALVIN J, SUGRUE D, PEIRCE T, GHAISAS N, HARKIN E, OCALLAGHAN T, MCHUGH P, NISAR S, DALY K, LAVIN F, SHAH P, JUNEJA R, MCGARRY K, JUNEJO S, MACMAHON B, PILLAY NP, LONG D, MAGUIRE C, MULDOON BC, SHIELS P, BANNAN L, CONNELLY E, BARTON J, MCCREERY C, QUIGLEY P, CASSIM S, NAIDOO DP, MYBURGH DP, MARX JD, COMMERFORD PJ, LAWRENSON J, THERON HD, RAJPUT MC, BENNETT JM, SARELI P, ARCE P, RICCITELLI MA, RYBA D, BECK E, DEMARTINI A, BORREGA NG, LAZZARI J, GONZALEZ M, LIPRANDI AS, MARTINEZ JM, SAMPO EA, BORTMAN G, GRANCELLI H, CARBAJALES J, GIROTTI A, MAUTNER B, GABRIELLI O, CAGIDE A, LAPUENTE A, ESPER R, TAKENS LJ, VANDERHEIJDEN MY, KRAGTEN JA, RENKENS R, TANS AC, GROSFELD MJW, KRUYSWIJK HH, DEGROOT A, LIEM KL, OLTHOF H, HAERKENSARENDS HE, HOOGHOUDT TEH, KUYPERS A, NIEMEYER MG, VANMANTGEM JP, AELFERS E, SLEGERS LC, SCHEFFER MG, DOEBE BO, SCHRIJVERS LEJM, VANWELY LR, HERWEIJER AH, DEMYTTENAERE M, PEERENBOOM P, BEKAERT I, SURMONT P, VANDORPE A, BEYS J, CLEMENT D, BENIT E, BEYLOOS M, DURIEUX C, BAYART M, HERSSENS M, CREMERS S, DEKEYSER F, VANWALLEGHEM U, HOPF R, MOLLER A, HAUBER J, HOFGARTNER F, SIGEL HA, GRIESHABER M, NEUBAUER M, RUDOLPH K, SEHNERT W, CARTSBURG R, KLEINE P, HENNECKE TH, KINDLER J, RAMME P, HELLMANN D, HEMMENFUNK DA, FREYTAG F, BECKER HJ, EISENMENGER A, FACH WA, BERNHARDT P, ERNST BKH, JACOB H, MALINOWSKI K, ROTH H, SIMON H, BIAS HJ, BISCHOFF KO, GERNER U, TORNOW P, JENSEN SG, MELLEMGAARD K, AMTOFT A, AXELSEN A, CHRISTENSEN C, HAUNSO S, JORGENSEN P, RASMUSSEN S, STRUNGE P, SVENDSEN TL, MADSEN H, NIELSEN W, EGEDE F, RASMUSSEN J, MARKENVARD J, MOLLERUP H, SIGURD B, KIRCHHOFF M, MCNAIR A, NIELSEN PE, NIELSEN JER, ANDERSEN MP, BUCHER E, ELLIOTT P, SLANY J, GRISOLD M, KLEIN W, ALDOR E, DORNAUS C, KAINZ W, MLCZOCH J, NOBIS H, TRINKS S, POHJOLASINTONEN S, NAUKKARINEN V, SIPILA R, NIKUS K, WINGREN PE, HARKONEN M, JAGERHOLM S, ELORANTA M, ISOJARVI J, SUHONEN O, KOSKELAINEN J, DECIAN F, VOLTA SD, BERTON G, CUCCHINI F, ABELLI I, GAZZOLA U, VILLANI GQ, CENTOFANTE P, MOSELE GM, VINCENZI M, ACCORSI F, DEITOS GA, DELAGARDELLE C, MUNCH U, VOGELIN HP.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
LANCET. 1993; 342(8875): 821-828.
Web of Science
PubMed
- Co-Autor*innen der Med Uni Graz
- Klein Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- Survival after acute myocardial infarction has been enhanced by treatment with thrombolytic agents, aspirin, and beta-adrenoceptor blockade. However there remains a substantial subgroup of patients who manifest clinical evidence of heart failure despite the first two of these treatments, and for whom beta-adrenoceptor antagonists are relatively or absolutely contraindicated. These patients have a greatly increased risk of fatal and non-fatal ischaemic, arrhythmic, and haemodynamic events. In this selected high-risk subset of patients we investigated the effect of therapy with the angiotensin converting enzyme (ACE) inhibitor rampiril, postulating that it would lengthen survival. 2006 patients who had shown clinical evidence of heart failure at any time after an acute myocardial infarction (AMI) were recruited from 144 centres in 14 countries. Patients were randomly allocated to double-blind treatment with either placebo (992 patients) or ramipril (1014 patients) on day 3 to day 10 after AMI (day 1). Patients with severe heart failure resistant to conventional therapy, in whom the attending physician considered the use of an ACE inhibitor to be mandatory, were excluded. Follow-up was continued for a minimum of 6 months and an average of 15 months. On intention-to-treat analysis mortality from all causes was significantly lower for patients randomised to receive ramipril (170 deaths; 17%) than for those randomised to receive placebo (222 deaths; 23%). The observed risk reduction was 27% (95 % Cl 11% to 40%; p = 0.002). Analysis of prespecified secondary outcomes revealed a risk reduction of 19% for the first validated outcome (i.e., first event in an individual patient)--namely, death, severe/resistent heart failure, myocardial infarction, or stroke (95% Cl 5% to 31%; p = 0.008). Oral administration of rampiril to patients with clinical evidence of either transient or ongoing heart failure, initiated between the second and ninth day after myocardial infarction, resulted in a substantial reduction in premature death from all causes. This benefit was apparent as early as 30 days and was consistent across a range of subgroups.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Double-Blind Method -
- Female -
- Heart Failure, Congestive - drug therapy
- Humans - drug therapy
- Male - drug therapy
- Middle Aged - drug therapy
- Myocardial Infarction - complications
- Proportional Hazards Models - complications
- Ramipril - adverse effects
- Risk Factors - adverse effects
- Survival Analysis - adverse effects
- Treatment Outcome - adverse effects